Hints and tips:
Related Topics
...The stalling has allowed Qsymia, a weight-loss drug made by Vivus, a rival US biotech, to gain a lead over Belviq, even though the drug was approved after Belviq by the FDA....
...For now, Mr Tam says Vivus is rebuffing alliances. “We have preferred to shake off suitors and do it alone to maintain value for our shareholders.”...
...The FDA is still considering similar diet drugs manufactured by Vivus and Orexigen Therapeutics. Their shares rose 7.4 per cent and 20.3 per cent, respectively, on Wednesday....
...Shares in Vivus gained 77.5 per cent to $18.73 after the drugmaker received backing from a US Food and Drug Administration advisory panel for a new weight loss pill....
...Shares in Vivus surged 90 per cent to as much as $20.12 in after-hours trading, after an advisory panel to the Food and Drug Administration voted overwhelmingly in favour of approving the company’s weight-loss...
...In the pharmaceutical sector, shares in Vivus lost 4 per cent to $9.28 after the company submitted an application to regulators for Qnexa, a drug designed to fight obesity....
...Vivus, the pharmaceutical company, was one of the biggest gainers on the market. Its shares rose 70.1 per cent to $11.80 after it said its weight-loss drug had met research goals....
International Edition